Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Concentrated autologous bone marrow mononuclear cells (ABM MNC) contain potentially therapeutic cell factors and past studies support therapeutic benefit to patients with cardiac diseases of acute myocardial infarction, ischemia, and heart failure when utilized as this study is designed. The purpose of the study is to determine the safety and efficacy of CardiAMP cell therapy system in patients with ischemic heart failure. It is a prospective, multi-center, randomized, controlled, patient and evaluator-blinded study comparing treatment with the CardiAMP cell therapy system to a control procedure with diagnostic catheterization.
Chronic heart failure is in need of new therapies. Over the past few years, cardiovascular regenerative medicine using bone marrow derived cells has emerged as a new treatment strategy that could have tremendous benefit in treating heart failure and are well supported by recent meta analyses of early clinical data sets. Concentrated autologous bone marrow mononuclear cells (ABM MNC) are the subject of the current study as they are supported by more clinical data than any other cell type described, and contain all of the potentially therapeutic cell factors from studies of selected cells. Study results demonstrate ABM MNC to be safe, and, when delivered intramyocardially as intended in the current study, results consistently support therapeutic benefit to patients with cardiac diseases of acute myocardial infarction, ischemia, and heart failure. The purpose of the study is to determine the safety and efficacy of CardiAMP cell therapy system in patients with ischemic heart failure. It is a prospective, multi-center, randomized, controlled, patient and evaluator-blinded study comparing treatment with the CardiAMP cell therapy system to a control procedure with diagnostic catheterization. The Treatment Group undergoes left ventricular catheterization and is treated with ABM MNC using the CardiAMP cell therapy system. The Control Group has a Control procedure consisting of left ventricular diagnostic catheterization but no introduction of the Helix transendocardial delivery catheter and no administration of ABM MNC.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Study (ABM MNC) Treatment | Experimental | Left ventricular catheterization with treatment consisting of autologous bone marrow mononuclear cells (ABM MNC) processed and delivered using the CardiAMP cell therapy system |
|
| Control Treatment | Sham Comparator | Left ventricular (diagnostic) catheterization but no administration of ABM MNC |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system | Device | the ABM MNC is obtained from the study patient via bone marrow aspiration in the hip and processed and delivered using the CardiAMP cell therapy system during the cardiac catheterization. |
| Measure | Description | Time Frame |
|---|---|---|
| Primary Efficacy Endpoint | The primary efficacy endpoint is the comparison of a composite score based on a 3-tiered Finkelstein-Schoenfeld (FS) hierarchical analysis. The tiers, starting with the most serious events, would be (1) all cause death, including cardiac death equivalents such as heart transplant or left ventricular assist device placement, ordered by time to event; (2) non-fatal MACCE events (heart failure hospitalization or a worsening heart failure, stroke or MI) ordered by time to event, excluding those deemed procedure related occurring within the first 7 days, and (3) change for quality of life as measured using the Minnesota Living with Heart Failure Questionnaire (MLwHFQ) | Follow-up duration at endpoint analysis ranges from a minimum of 12 to a maximum of 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| First Secondary Endpoint | Time to all-cause death, LVAD/heart transplant, or heart failure hospitalization | Baseline through study completion, maximum of two years |
| Second Secondary Endpoint | Cumulative heart failure hospitalizations |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Debby Holmes-Higgin, MS, MPH | Contact | 650-226-0120 | debbyhh@biocardia.com |
| Name | Affiliation | Role |
|---|---|---|
| Amish Raval, MD | University of Wisconsin, Madison | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Morton Plant Hospital - BayCare | Recruiting | Clearwater | Florida | 33756 | United States |
No plan at this time to make IPD available to other researchers.
Not provided
Not provided
Not provided
Not provided
Not provided
Controlled study of study treatment consisting of intramyocardial autologous cell injections compared to sham control, both performed in cardiac catheterization
Not provided
Not provided
Double-blind including study participants and care provider (investigator) conducting outcomes assessments
|
| Baseline through study completion, maximum of two years |
| Third Secondary Endpoint | Time to first heart failure hospitalization | Baseline through study completion, maximum of two years |
| Fourth Secondary Endpoint | Change in quality of life as measured using the MLwHF questionnaire based on a scale of 0-105, with 0 being best. | Baseline to 12 months, 24 months |
| Fifth Secondary Endpoint | Change in quality of life as measured using the Kansas City Cardiomyopathy questionnaire (KCCQ), based on a scale of 0-100, with 100 being best | Baseline to 12 months, 24 months |
| Sixth Secondary Endpoint | Change in functional capacity as measured using the 6-minute walk test (6MWT) | Baseline to 12 months, 24 months |
| Seventh Secondary Endpoint | Modified Primary Efficacy Endpoint consisting of all-cause death, LVAD/heart transplant, heart failure hospitalizations and worsening heart failure events treated as an outpatient but without a quality-of-life measure | Baseline through study completion, maximum of two years |
| Emory University | Recruiting | Atlanta | Georgia | 30322 | United States |
|
| Henry Ford Hospital | Recruiting | Detroit | Michigan | 48202 | United States |
|
| Cleveland Clinic | Withdrawn | Cleveland | Ohio | 44195 | United States |
| University of Wisconsin-Division of Cardiovascular Medicine | Recruiting | Madison | Wisconsin | 53792 | United States |
|